Brief: Nasdaq To Delist Lipigon Pharmaceuticals From First North Growth Market
04/05/2026 14:22
May 4 (Reuters) - Lipigon Pharmaceuticals AB LPGO.ST: NASDAQ DECIDES TO DELIST LIPIGON FROM THE FIRST NORTH GROWTH MARKET LIPIGON’S SHARES WILL CONTINUE TO BE TRADED UNTIL 18 MAY 2026 Source text: ID:nBQNR4cYF Further company coverage: LPGO.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Lipigon Pharmaceuticals AB
See all newsBrief: Nasdaq To Delist Lipigon Pharmaceuticals From First North Growth Market
Brief: Lipigon Expected To Be Removed From Trading On Nasdaq Stockholm On May 18
Brief: Lipigon Proposes To Delist Company From Nasdaq First NGM
Brief: Lipigon Pharmaceuticals Oct-Dec Oper Loss At SEK 7.2 Mln
Brief: Lipigon Pharmaceuticals Aims To Reduce Cost Base By Two-Thirds